Archive for the 'Onconase (ranpirnase)' Category

Onconase (ranpirnase) news feed.

Paper in Cell Cycle Reports Alfacell’s ONCONASE® Targets siRNA

Alfacell Corporation (Nasdaq: ACEL) today announced that a paper published in Cell Cycle (2008; Vol. 7, Issue 20) reports that ONCONASE (ranpirnase) targets small interfering RNA (siRNA), likely within the RNA-induced silencing complex (RISC) of the RNA interference (RNAi) mechanism. The paper is the result of research conducted by collaborators at the Brander Cancer Research

more

Alfacell: Malignant mesothelioma treatment trial fails to meet primary endpoint

Alfacell Corp. late Wednesday said results from its Phase IIIB clinical trial for Onconase, which was being studied as a potential treatment for unresectable malignant mesothelioma, didn’t meet the trial’s primary endpoint. The Somerset, N.J.-based biopharmaceutical company said a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one

more

Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program

Alfacell Corporation today announced that it has confirmed that 316 evaluable events (patient deaths) have occurred in the confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE (ranpirnase), for the treatment of patients with unresectable malignant mesothelioma (UMM). In accordance with the statistical plan for the trial, the company has begun the process necessary

more

Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories

Somerset, NJ – Alfacell Corporation today announced that it has entered into a purchase and supply agreement with Scientific Protein Laboratories LLC (SPL) for the commercial production of ONCONASE(R) (ranpirnase). ONCONASE, the company’s lead drug candidate, is currently being evaluated as a treatment for unresectable malignant mesothelioma (UMM) in a confirmatory Phase IIIb clinical trial.

more

Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. and Alfacell Corporation today announced that they have entered into an exclusive licensing agreement under which Strativa has acquired the commercialization rights in the United States and its territories to ONCONASE(R) (ranpirnase) from Alfacell. ONCONASE is in Phase III

more

Alfacell Announces Third-Quarter Financial Results and Highlights

Alfacell Corporation (Nasdaq: ACEL) today announced its financial results and highlights for the quarter ended April 30, 2007. The company reported a net loss of approximately $2 million, or 4 cents per basic and diluted share, for the quarter ended April 30, 2007, compared to a loss of $1.7 million, or 5 cents per basic

more

ONCONASE® has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting

ONCONASE (ranpirnase), Alfacell Corporation’s lead drug candidate, may have potential as a chemopreventive agent, according to world-renowned mesothelioma researcher Michele Carbone M.D., Ph.D., at this week’s American Association for Cancer Research (AACR) Annual Meeting. In a series of poster presentations, Dr. Carbone highlighted the growing worldwide problem of asbestos exposure and its link to malignant

more

Preclinical Data Show Alfacell’s Onconase® Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells

Alfacell Corporation today announced that in vivo and in vitro preclinical data presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting show that Onconase (ranpirnase) significantly inhibits tumor growth of non-small cell lung cancer (NSCLC) and breast cancer cells. In the poster titled “Increased apoptosis and reduced lactate levels by

more

Alfacell Corporation Granted U.S. Orphan Drug Designation for ONCONASE® for Treatment of Malignant Mesothelioma: First-in-Class RNAi Drug in Phase IIIB Confirmatory Trial for Unresectable

Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease therapeutics for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation in the United States for the company’s lead drug candidate, ONCONASE® (ranpirnase), for treatment of malignant mesothelioma. Alfacell is evaluating ONCONASE

more

Alfacell Corporation Files for U.S. Orphan Drug Designation for ONCONASE®

Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease therapeutics for cancer, today announced it has filed an application with the U.S. Food and Drug Administration (FDA) to obtain orphan designation for its lead drug candidate ONCONASE® (ranpirnase) for the treatment of patients with unresectable malignant mesothelioma

more

Alfacell Corporation and GENESIS Pharma S.A. Announce Exclusive Licensing Agreement for ONCONASE in Southeast Europe

Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease therapeutics for cancer, today announced that it has entered into a exclusive licensing and distribution agreement with GENESIS Pharma S.A., for the commercialization of ONCONASE® (ranpirnase), the Company’s lead drug candidate. ONCONASE is currently being evaluated in a

more

Alfacell Corporation Announces Company Succession Plan

Alfacell Corporation (Nasdaq: ACEL) today announced that its Board of Directors has formed a search committee to recruit a President and Chief Operating Officer, a newly-created position at the company. The committee is chaired by David Sidransky, M.D., Chairman of the Scientific Advisory Board, and includes Kuslima Shogen, Chairman and CEO, and James Loughlin, C.P.A.,

more

Further Analysis of Phase III Data Using CALGB and EORTC Paradigms Reinforces Survival Benefits of ONCONASE® for the Treatment of Patients with Mesothelioma

Alfacell Corporation (NASDAQ: ACEL) today announced results from further detailed analysis of the company's previously reported Phase IIIa clinical trial of ONCONASE® (ranpirnase) versus doxorubicin for the treatment of unresectable malignant mesothelioma (UMM). The post-hoc analysis found that patients treated with ONCONASE had greater median survival times than patients treated with doxorubicin alone using the

more

Alfacell Updates Progress on Clinical Development Program for ONCONASE® in Malignant Mesothelioma

Alfacell Corporation (Nasdaq: ACEL – News) announced today an update regarding the ongoing randomized, multi-center, multi-national, confirmatory Phase IIIb registration study for its lead anti-cancer drug, ONCONASE® (ranpirnase). This pivotal trial is evaluating the effectiveness of ONCONASE plus doxorubicin in improving the survival of patients with unresectable malignant mesothelioma (UMM) over doxorubicin alone. The Company’s

more

New Research Findings Published in National Academy of Sciences Journal Show Unique Promise of ONCONASE in the Prevention and Treatment of Mesothelioma and Lung Cancer Caused by Asbestos

Alfacell Corporation (Nasdaq: ACEL) announced today that groundbreaking, independent new research findings show that the elusive molecular mechanism that asbestos uses to provoke lung cancer may have been identified. The research also found that ONCONASE® (ranpirnase) may be one of the most effective methods of treatment for mesothelioma and lung cancer caused by this mechanism,

more

Last update: April 01, 2019. 03:30:08 pm.